Fig. 3: Macrophage-expressed SLC2A1 determines the therapeutic efficacy of SLC2A1 inhibition.
a, Flow cytometry assays and summarized data of 2-NBDG (glucose analogue) uptake by tumour cells (left) and TAMs (right) (control group (n = 5) and BAY-876-treated group (n = 4)). b, Growth curves (by volume) of LLC-Slc2a1KD or LLC-vector control allograft tumours in C57BL/6 mice (BAY-876-treated groups (n = 4 each) and the other groups (n = 5 each)) treated with BAY-876 or vehicle. c, Growth curves of LLC allograft tumours in C57BL/6J following BAY-876 treatment with or without αCSF1R antibody (n = 6). d–f, Percentage (left) and number (right) of CD8+ T cells (d) and CD8⁺ T cell populations expressing IFN-γ (e) and TNF (f) (n = 6). g, Growth curves of subcutaneous LLC tumours in Slc2a1fl/fl (n = 6) and Slc2a1cko (n = 7) mice. h, Growth curves of subcutaneous LLC tumours in Slc2a1cko mice treated with BAY-876 or dimethyl sulfoxide (DMSO) control (n = 4). i–k, Schematic of the experimental design for co-implantation of TC-1 cells with TAMs from Slc2a1fl/fl or Slc2a1cko LLC tumour-bearing mice (i), tumour growth curves (j) and weights (k) for groups from i (Slc2a1fl/fl group (n = 6) and Slc2a1cko group (n = 5)). Data are reported as the mean ± s.e.m., and group differences were assessed by a two-tailed unpaired Student’s t-test.
